Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000084.xml
Synthesis 2011(16): 2619-2624
DOI: 10.1055/s-0030-1260116
DOI: 10.1055/s-0030-1260116
PAPER
© Georg Thieme Verlag
Stuttgart ˙ New York
A Concise Synthesis of 6-Oxa-3-azabicyclo[3.1.1]heptane Hydrotosylate
Further Information
Received
4 May 2011
Publication Date:
14 July 2011 (online)
Publication History
Publication Date:
14 July 2011 (online)

Abstract
Bridged bicyclic morpholines are important building blocks in medicinal chemistry research. The bicyclic morpholine 6-oxa-3-azabicyclo[3.1.1]heptane (2a) is of particular interest as a morpholine isostere because it is achiral and shows properties similar to that of morpholine based on a derived analogue. The first synthesis of morpholine 2a (tosylate salt) is described. The six-step sequence begins with inexpensive starting materials and uses straightforward chemistry.
Key words
stereoselective synthesis - bicyclic compounds - heterocycles - alkylation - hydrogenation
- Supporting Information for this article is available online:
- Supporting Information
- 1
Brickner SJ.Barbachyn MR.Hutchinson DK.Manninen PR. J. Med. Chem. 2008, 51: 1981 - 2
Barker AJ.Gibson KH.Grundy W.Godfrey AA.Barlow JJ.Healy MP.Woodburn JR.Ashton SE.Curry BJ.Scarlett L.Henthorn L.Richards L. Bioorg. Med. Chem. Lett. 2001, 11: 1911 - 3
Kasper S.El Giamal N.Hilger E. Expert Opin. Pharmacother. 2000, 1: 771 -
4a
Griffin RJ.Fontana G.Golding BT.Guiard S.Hardcastle IR.Leahy JJJ.Martin N.Richardson C.Rigoreau L.Stockley M.Smith GCM. J. Med. Chem. 2005, 48: 569 -
4b
Blizzard TB.DiNinno F.Morgan JD.Chen HY.Wu JY.Gude C.Kim S.Chan W.Birzin ET.Yang YT.Pai L.-Y.Zhang Z.Hayes EC.DaSilva CA.Tang W.Rohrer SP.Schaeffer JM.Hammond ML. Bioorg. Med. Chem. Lett. 2004, 14: 3861 -
4c
Roecker AJ.Coleman PJ.Mercer SP.Schreier SD.Buser CA.Walsh ES.Hamilton K.Lobell RB.Tao W.Diehl RE.South VJ.Davide JP.Kohl NE.Yan Y.Kuo LC.Li C.Fernandez-Metzler C.Mahan EA.Prueksaritanont T.Hartman GD. Bioorg. Med. Chem. Lett. 2007, 17: 5677 -
4d
Venkatesan AM.Chen Z.Santos OD.Dehnhardt C.Santos ED.Ayral-Kaloustian S.Mallon R.Hollander I.Feldberg L.Lucas J.Yu K.Chaudhary I.Mansour TS. Bioorg. Med. Chem. Lett. 2010, 20: 5869 -
4e
Zask A.Kaplan J.Verheijen JC.Richard DJ.Curran K.Brooijmans N.Bennett EM.Toral-Barza L.Hollander I.Ayral-Kaloustian S.Yu K. J. Med. Chem. 2009, 52: 7942 -
4f
Tsuo H.-R.MacEwan G.Birnberg G.Zhang N.Brooijmans N.Toral-Barza L.Hollander I.Ayral-Kaloustian S.Yu K. Bioorg. Med. Chem. Lett. 2010, 20: 2259 - 5
Wuitschik G.Carreira EM.Wagner B.Fischer H.Parrilla I.Schuler F.Rogers-Evans M.Müller K. J. Med. Chem. 2010, 53: 3227 -
6a
Newth FH.Wiggins LF. J. Chem. Soc. 1948, 155 -
6b
Connolly TJ.Considine JL.Ding Z.Forsatz B.Jennings MN.MacEwan MF.McCoy KM.Place DW.Sharma A.Sutherland K. Org. Process Res. Dev. 2010, 14: 459 -
7a
v. Braun J.Leistner W. Chem. Ber. 1926, 59: 2323 -
7b
Axten JM,Brady GP,Gallagher TF,Heerding DA,Medina JR, andRomeril SP. inventors; WO 2010,120,854. ; Chem. Abstr. 2010, 153, 555216 - 8
Portoghese PS.Turcotte JG. J. Med. Chem. 1971, 14: 288 - 9
Flohr A,Jakob-Roetne R,Norcross RD, andRiemer C. inventors; WO 2003,049,741. ; Chem. Abstr. 2003, 139, 53026 - 10
Wuitschik G.Rogers-Evans M.Buckl A.Bernasconi M.Märki M.Godel T.Fischer H.Wagner B.Parrilla I.Schuler F.Schneider J.Alker A.Schweizer WB.Müller K.Carreira EM. Angew. Chem. Int. Ed. 2008, 47: 4512 -
11a
Paul R.Williams RP.Cohen E. J. Org. Chem. 1975, 40: 1653 -
11b
Pearlman BA. inventors; WO 1999,024,393. ; Chem. Abstr. 1999, 130, 338099 -
11c
Perrault WR.Pearlman BA.Godrej DB.Jeganathan A.Yamagata K.Chen JJ.Lu CV.Herrington PM.Gadwood RC.Chan L.Lyster MA.Maloney MT.Moeslein JA.Greene ML.Barbachyn MR. Org. Process Res. Dev. 2003, 7: 533 -
12a
Higgins RH.Eaton QL.Worth L.Peterson MV. J. Heterocycl. Chem. 1987, 24: 255 -
12b
Higgins RH.Watson MR.Faircloth WJ.Eaton QL.Jenkins H. J. Heterocycl. Chem. 1988, 25: 383 - 13 Cf:
Morie T.Kato S.Harada H.Matsumoto J. Heterocycles 1994, 38: 1033 - 14 The importance of forming a potassium
enolate to effect efficient intramolecular cyclization on a similar
carbocyclic system has been previously observed, see:
Nicolaou KC.Magolda RL.Claremon DA. J. Am. Chem. Soc. 1980, 102: 1404 - 15
Geiger C.Zelenka C.Lehmkuhl K.Schepmann D.Englberger W.Wünsch B. J. Med. Chem. 2010, 53: 4212 - 16
Ohkubo M.Kuno A.Katsuta K.Ueda Y.Shirakawa K. Chem. Pharm. Bull. 1996, 44: 778 - 17 Cf:
Sasaki T.Eguchi S.Suzuki T. J. Org. Chem. 1980, 45: 3824 - 18
Di L.Kerns EH.Hong Y.Chen H. Int. J. Pharm. 2005, 297: 110
References and notes
Conditions used in the workup of the borane reduction of compound 12, see experimental section for further details.